- Home
- SVT vs EQ Comparison
SVT vs EQ Comparison
Compare SVT & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVT
- EQ
- Stock Information
- Founded
- SVT 1959
- EQ 2017
- Country
- SVT United States
- EQ United States
- Employees
- SVT N/A
- EQ N/A
- Industry
- SVT Industrial Machinery/Components
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- SVT Consumer Discretionary
- EQ Health Care
- Exchange
- SVT Nasdaq
- EQ Nasdaq
- Market Cap
- SVT 27.1M
- EQ 31.1M
- IPO Year
- SVT N/A
- EQ 2018
- Fundamental
- Price
- SVT $10.60
- EQ $0.88
- Analyst Decision
- SVT
- EQ Buy
- Analyst Count
- SVT 0
- EQ 2
- Target Price
- SVT N/A
- EQ $5.00
- AVG Volume (30 Days)
- SVT 1.7K
- EQ 2.2M
- Earning Date
- SVT 03-21-2025
- EQ 03-24-2025
- Dividend Yield
- SVT N/A
- EQ N/A
- EPS Growth
- SVT N/A
- EQ N/A
- EPS
- SVT 0.05
- EQ N/A
- Revenue
- SVT $47,487,000.00
- EQ $45,914,000.00
- Revenue This Year
- SVT N/A
- EQ $4.77
- Revenue Next Year
- SVT N/A
- EQ N/A
- P/E Ratio
- SVT $223.96
- EQ N/A
- Revenue Growth
- SVT 19.50
- EQ 7.70
- 52 Week Low
- SVT $10.16
- EQ $0.49
- 52 Week High
- SVT $13.85
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- SVT 47.50
- EQ 58.42
- Support Level
- SVT $10.26
- EQ $0.85
- Resistance Level
- SVT $10.66
- EQ $0.98
- Average True Range (ATR)
- SVT 0.34
- EQ 0.10
- MACD
- SVT -0.04
- EQ 0.01
- Stochastic Oscillator
- SVT 36.50
- EQ 62.50
About SVT Servotronics Inc.
Servotronics Inc is a U.S based company that designs, manufactures, and markets servo valves, including torque motor, hydraulic, and pneumatic valves. The company has single reportable segment which is aerospace Its products are marketed and sold throughout the United States and in select foreign markets. These products are sold to commercial aviation manufacturers, government prime contractors, government subcontractors, and end-users.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.